论文部分内容阅读
细胞基因工程技术发展为治疗诸如帕金森病等神经细胞变性疾病提供了广阔的前景,人们开始考虑移植基因工程细胞,例如胚胎多巴胺能细胞移植,转基因的原代细胞包括原代非神经细胞和原代神经细胞移植,以及神经干细胞移植,把它作为生物微泵以产生治疗因子,以期能恢复或改善黑质纹状体多巴胺系统功能。胚胎组织移植对于不断增加的病人数来说显得并不太可行。人们正在研究这些决定成人大脑中神经干细胞分化的刺激信号。也许不久的将来,转基因的原代细胞和神经干细胞就可以广泛用于治疗。
Advances in cellular genetic engineering have offered broad prospects for the treatment of degenerative diseases of neuronal cells such as Parkinson’s disease. People began to consider transplanting genetically engineered cells, such as embryonic dopaminergic cells, and primary transgenic cells including primary non-neuronal cells and primary Transplantation of neural stem cells, and neural stem cell transplantation, as a biological micro-pump to produce therapeutic factors in order to restore or improve nigrostriatal dopamine system function. Embryonic tissue transplantation is not feasible for a growing number of patients. People are studying these signals that determine neural stem cell differentiation in adult brains. Perhaps in the near future, transgenic primary cells and neural stem cells will be widely available for treatment.